Post-CAR T

Optimizing the Post-CAR T Monitoring Period

Al-Ola A Abdallah, Associate Professor and Plasma Cell Disorder Program Director at Division of HMCT/University of Kansas Medical Center, shared a paper by Nausheen Ahmed et al on X:

“Out in press by Nausheen Ahmed and colleagues for ASH. Optimizing the Post-CAR T Monitoring Period for Axicabtagene Ciloleucel, Tisagenlecleucel, and Lisocabtagene Maraleucel.

  • NRM beyond day 28 is largely driven by infection
  • New-onset CRS and ICANS is rare after 2 weeks”

Post-CAR T

Source: Al-Ola A Abdallah/X

Post-CAR T

Authors: Nausheen Ahmed, William Wesson, Forat Lutfi, David L. Porter, Veronika Bachanova, Loretta J. Nastoupil, Miguel-Angel Perales, Richard T. Maziarz, Jamie Brower, Gunjan L Shah, Andy I. Chen, Olalekan O. Oluwole, Stephen J. Schuster, Michael R Bishop, Joseph P. McGuirk, Peter A. Riedell

Optimizing the Post-CAR T Monitoring Period for Axicabtagene Ciloleucel, Tisagenlecleucel, and Lisocabtagene Maraleucel

Al-Ola A Abdallah Andy I. Chen ASH cancer David L. Porter Forat Lutfi Gunjan L. Shah Jamie Brower Joseph P. McGuirk Loretta J. Nastoupil Michael R Bishop Miguel-Angel Perales Nausheen Ahmed Olalekan O. Oluwole OncoDaily Oncology Peter A. Riedell Plasma cell disorder Post-CAR T Richard T. Maziarz Stephen J. Schuster University of Kansas Medical Center Veronika Bachanova William Wesson